【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 11
1.2 List of Figures 13
2 Introduction 15
2.1 What Is This Report About? 15
3 Definitions of Markets/Categories Covered 16
3.1 Cardiovascular Devices 16
3.1.1 Electrophysiology 16
3.1.2 Peripheral Vascular Devices 16
3.2 Nephrology and Urology Devices 16
3.2.1 Incontinence Devices 16
3.3 Drug Delivery Devices 16
3.3.1 Central Venous Catheters 16
4 Company Snapshot 17
4.1 Key Facts 17
4.2 Company Overview 17
4.3 Financial Performance 17
4.4 SWOT Snapshot 17
5 Business Description 18
5.1 Business Overview 18
5.2 Oncology Product Line 18
5.2.1 Overview 18
5.2.2 Financials 18
5.3 Other Products Product Line 18
5.3.1 Overview 18
5.3.2 Financials 18
5.4 Surgical Specialties Product Line 18
5.4.1 Overview 18
5.4.2 Financials 19
5.5 Urology Product Line 19
5.5.1 Overview 19
5.5.2 Financials 19
5.6 Vascular Product Line 19
5.6.1 Overview 19
5.6.2 Financials 20
5.6.3 Market View 20
5.7 Major Products and Services 20
5.7.1 Overview 20
6 History 22
7 SWOT Analysis 25
7.1 Overview 25
7.2 C. R. Bard, Inc. Strengths 25
7.2.1 Diversified Business Operations 25
7.2.2 Sturdy Research and Development Activities 26
7.2.3 Constant Growth in Revenues 26
7.3 C. R. Bard, Inc. Weaknesses 26
7.3.1 Legal Proceedings and Product Recalls 26
7.3.2 Dependence on the US Market 26
7.4 C. R. Bard, Inc. Opportunities 27
7.4.1 Expansion through Acquisitions 27
7.4.2 Pipeline Clinical Trials 27
7.4.3 Global Nephrology and Urology Devices Market 27
7.5 C. R. Bard, Inc. Threats 28
7.5.1 Stringent Government Regulations 28
7.5.2 Shift in Technology 28
7.5.3 Healthcare Reform Bill 28
8 Competitors 29
9 Competitive Landscape 30
9.1 Cardiovascular Devices (Peripheral Vascular Devices), Global, Market Share (%), 2011 30
9.2 C. R. Bard, Inc., Cardiovascular Devices (Peripheral Vascular Devices), by Region, Market Share (2011) 32
9.3 C. R. Bard, Inc., Cardiovascular Devices (Peripheral Vascular Devices), by Country, Market Share (2011) 33
9.4 Cardiovascular Devices (Electrophysiology), Global, Market Share (%), 2011 35
9.5 C. R. Bard, Inc., Cardiovascular Devices (Electrophysiology), by Region, Market Share (2011) 37
9.6 C. R. Bard, Inc., Cardiovascular Devices (Electrophysiology), by Country, Market Share (2011) 38
9.7 Drug Delivery Devices (Central Venous Catheters), Global, Market Share (%), 2011 40
9.8 C. R. Bard, Inc., Drug Delivery Devices (Central Venous Catheters), by Region, Market Share (2011) 42
9.9 C. R. Bard, Inc., Drug Delivery Devices (Central Venous Catheters), by Country, Market Share (2011) 43
9.10 Nephrology and Urology Devices (Incontinence Devices), Global, Market Share (%), 2011 45
9.11 C. R. Bard, Inc., Nephrology and Urology Devices (Incontinence Devices), by Region, Market Share (2011) 47
9.12 C. R. Bard, Inc., Nephrology and Urology Devices (Incontinence Devices), by Country, Market Share (2011) 48
10 C. R. Bard, Inc. Medical Equipment Market Share Analysis by Category 50
10.1 C. R. Bard, Inc., Global, Category Revenue Share (2011) 50
10.2 C. R. Bard, Inc., Asia-Pacific, Category Revenue Share (2011) 52
10.2.1 C. R. Bard, Inc., Australia, Category Revenue Share (2011) 54
10.2.2 C. R. Bard, Inc., China, Category Revenue Share (2011) 56
10.2.3 C. R. Bard, Inc., India, Category Revenue Share (2011) 58
10.2.4 C. R. Bard, Inc., Japan, Category Revenue Share (2011) 60
10.2.5 C. R. Bard, Inc., Other Asia-Pacific, Category Revenue Share (2011) 62
10.3 C. R. Bard, Inc., Europe, Category Revenue Share (2011) 64
10.3.1 C. R. Bard, Inc., France, Category Revenue Share (2011) 66
10.3.2 C. R. Bard, Inc., Germany, Category Revenue Share (2011) 68
10.3.3 C. R. Bard, Inc., Italy, Category Revenue Share (2011) 70
10.3.4 C. R. Bard, Inc., Spain, Category Revenue Share (2011) 72
10.3.5 C. R. Bard, Inc., United Kingdom, Category Revenue Share (2011) 74
10.3.6 C. R. Bard, Inc., Other Europe, Category Revenue Share (2011) 76
10.4 C. R. Bard, Inc., Middle East and Africa, Category Revenue Share (2011) 78
10.5 C. R. Bard, Inc., North America, Category Revenue Share (2011) 80
10.5.1 C. R. Bard, Inc., Canada, Category Revenue Share (2011) 82
10.5.2 C. R. Bard, Inc., United States, Category Revenue Share (2011) 84
10.6 C. R. Bard, Inc., South and Central America, Category Revenue Share (2011) 86
10.6.1 C. R. Bard, Inc., Brazil, Category Revenue Share (2011) 88
10.6.2 C. R. Bard, Inc., Other South and Central America, Category Revenue Share (2011) 90
11 Key Employees 92
12 Key Employee Biographies 93
13 Company Statement 94
14 Locations And Subsidiaries 97
14.1 Head Office 97
14.2 Other Locations & Subsidiaries 97
15 Financial Deals Landscape 101
15.1 C. R. Bard, Inc., Deals Volume Summary, 2007 to 2012 101
16 C. R. Bard, Inc. Detailed Deal Summary 103
16.1 Asset Purchase 103
16.1.1 PacerView Technologies Sells PacerView Technology To Bard Access Systems 103
16.1.2 Spire Completes Sale Of Hemodialysis Catheter Business To Bard Access Systems For $12.5 Million 104
16.1.3 Davol Acquires XenMatrix From Brennen Medical For $17 Million 106
16.1.4 Edwards Lifesciences Sells LifeStent Product Line Assets To C. R. Bard For $140 Million 107
16.1.5 C. R. Bard Acquires Assets From Inrad 109
16.1.6 C. R. Bard Acquires EasyTac From Agency for Medical Innovations 110
16.2 Venture Financing 111
16.2.1 NeoMend Secures $10 Million In Financing 111
16.2.2 Lutonix Secures $10 Million In Series C Financing 112
16.2.3 Neomend Raises $33 Million In Venture Financing 113
16.2.4 NeoMend Secures $30 Million In Series D Financing Round 115
16.2.5 Medivance Secures $8 Million In New Venture Financing Round 117
16.2.6 Lutonix Secures $20 Million In Series B Financing 118
16.2.7 NeoMend Secures An Additional $15 Million In Series C Financing 119
16.2.8 FlowCardia Raises $30 Million In Series C Financing 120
16.2.9 NeoMend Secures $10.02 Million In Series C Funding 122
16.2.10 Lutonix Secures $5 Million In Series A Financing 123
16.3 Private Equity 124
16.3.1 Protostar Equity Partners Acquires Minority Stake In SenoRx 124
16.4 Partnerships 125
16.4.1 Covalon Technologies Expands Agreement With C. R. Bard 125
16.4.2 Covalon Technologies Signs Licensing Agreement With C. R. Bard 126
16.4.3 ClearStream Technologies Enters Into Licensing Agreement With C. R. Bard 127
16.4.4 C. R. Bard Signs Licensing Agreement With Genzyme 128
16.4.5 TyRx Pharma Enters Into Licensing Agreement With C. R. Bard 129
16.4.6 RTI Biologics Expands Distribution Agreement With Davol For Tutoplast Sterilized Dermal Allografts 130
16.4.7 Terason Ultrasound Enters Into Technology Integration Agreement With SenoRx 131
16.4.8 Medegen Signs An Agreement With C. R. Bard 132
16.4.9 IDev Technologies Enters Into A Distribution Agreement With YMed 133
16.4.10 Maelor Enters Into Distribution Agreement With Bard Limited 134
16.4.11 Cordis Enters Into Distribution Agreement With ClearStream Technologies 135
16.5 Equity Offering 136
16.5.1 ClearStream Technologies Completes Private Placement For $2 Million 136
16.5.2 ClearStream Technologies Completes Private Placement Of $5.6 Million 137
16.5.3 ClearStream Technologies Completes Private Placement Of $0.92 Million 138
16.5.4 ClearStream Technologies Completes Private Placement Of $1.8 Million 139
16.5.5 SenoRx Completes IPO Of $50.6 Million 140
16.5.6 C. R. Bard Completes Public Offering Of Senior Unsecured Notes Due 2016 For $250 Million 141
16.5.7 C. R. Bard Completes Public Offering Of Senior Unsecured Notes Due 2021 For $500 Million 143
16.6 Acquisition 145
16.6.1 C. R. Bard Acquires Lutonix 145
16.6.2 C. R. Bard Completes Acquisition Of Medivance For $250 Million 146
16.6.3 C. R. Bard Completes Acquisition Of Clearstream Technologies For $69 Million 148
16.6.4 C. R. Bard Completes Acquisition Of SenoRx For $213 Million 150
16.6.5 C.R. Bard Acquires Remaining 15% Stake In Bard Sendirian For $26 Million 152
16.6.6 C. R. Bard Completes Acquisition Of FlowCardia For $80.1 Million 153
16.6.7 C. R. Bard Acquires Y-Med For $35.3 Million 155
16.6.8 C. R. Bard Acquires Specialized Health Products International For $68 Million 156
17 Recent Developments 158
17.1 Strategy And Business Planning 158
17.1.1 May 10, 2012: C R Bard Creates 200 New Jobs Through Puerto Rican Expansion 158
17.1.2 Dec 13, 2010: Bard To Improve Overall Cost Structure And Enhance Operational Effectiveness 158
17.2 Financial Announcements 159
17.2.1 Jan 31, 2013: Bard Reports Revenue Of $3 Billion In 2012 159
17.2.2 Oct 23, 2012: Bard Reports Revenue Of $722.9m In Q3 2012 160
17.2.3 Jul 25, 2012: Bard Reports Revenue Of $742.6m In Q2 2012 160
17.2.4 Apr 24, 2012: Bard Reports Revenue Of $730m In Q1 2012 160
17.2.5 Jan 31, 2012: Bard Reports Revenue Of $2.9 Billion In 2011 161
17.2.6 Oct 25, 2011: Bard Reports Revenues Of $719.2m In Q3 2011 161
17.2.7 Jul 21, 2011: Bard Reports Net Sales Of $725m In Q2 2011 162
17.2.8 Apr 21, 2011: Bard Reports Net Sales Of $700.3m In Q1 2011 162
17.2.9 Jan 31, 2011: Bard Reports Net Sales of $2.72 Billion In 2010 163
17.2.10 Oct 21, 2010: Bard Reports Net Income Of $127.50 Million In Q3 2010 163
17.2.11 Jul 22, 2010: Bard Reports Net Income Of $124.7 Million For Q2 2010 164
17.2.12 Apr 22, 2010: Bard Reports Net Income Of $121.2 Million In Q1 2010 164
17.2.13 Jan 28, 2010: Bard Reports Net Income Of $461.4 Million In 2009 165
17.2.14 Oct 21, 2009: C.R. Bard Reports Net Income Of $130 Million In Q3 2009 165
17.2.15 Jul 22, 2009: Bard Posts Net Income Of $112.2 Million For Q2 2009 166
17.2.16 Jul 22, 2009: CR Bard Q2 Net Income Up 44% 166
17.2.17 Apr 22, 2009: Bard Posts Net Income Of $112.5 Million For Q1 2009 167
17.2.18 Jan 29, 2009: Bard Reports 2008 Results 167
17.2.19 Dec 10, 2008: Bard Reports Quarterly Dividend 168
17.2.20 Oct 22, 2008: Bard Reports 3Q 2008 Results 168
17.2.21 Oct 15, 2008: Bard To Declare 3Q 2008 Results 168
17.2.22 Oct 08, 2008: Bard Reports Quarterly Dividend 168
17.2.23 Jul 23, 2008: Bard Declares 2Q 2008 Results 169
17.2.24 Jun 11, 2008: Bard Reports Quarterly Dividend 169
17.2.25 Apr 23, 2008: Bard Reports Q1 2008 Results 170
17.2.26 Apr 16, 2008: Bard Reports Quarterly Dividend 170
17.2.27 Apr 15, 2008: Bard To Declare Q1 2008 Results 170
17.2.28 Jan 31, 2008: Bard Reports Q4 2007 Results 171
17.2.29 Dec 12, 2007: Bard Declares Quarterly Dividend 171
17.2.30 Oct 23, 2007: Bard Reports Q3 2007 Results 172
17.2.31 Oct 10, 2007: Bard Declares Quarterly Dividend 173
17.2.32 Oct 10, 2007: Bard Announces Share Repurchase Program 173
17.2.33 Jul 24, 2007: Bard Reports Q2 2007 Results 173
17.2.34 Jun 13, 2007: Bard Declares Quarterly Dividend 174
17.2.35 Apr 24, 2007: Bard Reports Q1 2007 Results 174
17.2.36 Apr 18, 2007: Bard Declares Quarterly Dividend 175
17.2.37 Jan 25, 2007: Bard Reports Q4 2006 Results 175
17.3 Corporate Communications 177
17.3.1 Nov 26, 2012: C.R. Bard To Lay Off 54 Workers From Queensbury Plant 177
17.3.2 Apr 30, 2012: C R Bard Appoints Christopher S Holland As CFO 177
17.3.3 Dec 02, 2011: C.R. Bard Plans To Cut 50 Jobs From Queensbury Plant 177
17.3.4 Aug 01, 2011: Bard Announces Retirement Of Todd Schermerhorn As Senior Vice President And CFO 178
17.3.5 Feb 10, 2011: C.R. Bard To Cut 200 Jobs From Queensbury Plant 178
17.3.6 Feb 10, 2011: Bard Appoints Todd Garner As Vice President, Investor Relations 178
17.3.7 Feb 10, 2011: C. R. Bard To Reduce Workforce By 20% 179
17.3.8 Apr 13, 2009: Bard Announces Promotion Of Jim C. Beasley To Group Vice President 179
17.3.9 Jun 25, 2008: Bard Announces Executive Promotion 179
17.4 Legal and Regulatory 180
17.4.1 Jan 15, 2013: C R Bard Wins Round As Supreme Court Rejects Gore Patent Appeal 180
17.4.2 Aug 06, 2012: Jury Returns $5.5m Verdict Against C.R. Bard In Transvaginal Mesh Lawsuit 180
17.4.3 Jul 06, 2011: C.R. Bard Extends Settlement In Kugel Mesh Litigation 181
17.4.4 Aug 18, 2010: Atrium Responds To Bard Suit 181
17.4.5 Mar 11, 2010: FDA Issues Warning On Counterfeit Surgical Mesh 182
17.4.6 Sep 29, 2009: Bard Gets Favorable Ruling In Class Action Lawsuit 183
17.4.7 Jul 30, 2008: US District Court Rules In Favor Of Bard On Patent Violation Suit Against Gore 183
17.5 Product News 183
17.5.1 Nov 02, 2012: C. R. Bard Receives FDA 510(k) Approval For Ajust Helical Adjustable Single Incision Sling 183
17.5.2 Jul 27, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 184
17.5.3 Jul 25, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 184
17.5.4 Jun 15, 2010: C.R. Bard Announces Publication Of RESILIENT Trial Results Of Bard LIFESTENT Vascular Stent 185
17.5.5 Feb 16, 2010: C.R. Bard To Complete Clinical Trial For Bard Ventrio Hernia Patch In First Half Of 2011 186
17.5.6 Sep 08, 2009: Bard To Complete Phase I Trial For RESTORe Suturing System In Second Half Of 2010 186
17.5.7 Sep 02, 2009: Bard To Complete The Phase III Trial For BARD HD MESH Ablation System In First Half Of 2011 186
17.5.8 Jul 22, 2009: C.R. Bard Plans To Introduce Ultraverse.018 Balloon 187
17.5.9 Jul 22, 2009: C.R. Bard Plans To Launch .014 Ultra Low Profile Balloon 187
17.5.10 Jul 22, 2009: C.R. Bard Plans To Launch LifeStent Product Enhancements 187
17.5.11 Feb 17, 2009: C. R. Bard Receives US FDA Approval To Market LifeStent FlexStar Vascular Stent Systems 187
17.5.12 Dec 08, 2008: Bard Receives FDA Approval For The E-Luminexx Vascular Stent 188
17.5.13 Aug 20, 2008: C. R. Bard Inc. Published Clinical Study Results Of Agento I.C. Silver-Coated Endotracheal Tube 188
17.5.14 Nov 08, 2007: Bard Receives Clearance To Market Agento IC Silver-Coated Endotracheal Tube 188
17.6 Product Approvals 189
17.6.1 Nov 02, 2012: C. R. Bard Receives FDA 510(k) Approval For Ajust Helical Adjustable Single Incision Sling 189
17.6.2 Feb 17, 2009: C. R. Bard Receives US FDA Approval To Market LifeStent FlexStar Vascular Stent Systems 189
17.6.3 Dec 08, 2008: Bard Receives FDA Approval For The E-Luminexx Vascular Stent 190
17.6.4 Nov 08, 2007: Bard Receives Clearance To Market Agento IC Silver-Coated Endotracheal Tube 190
17.7 Clinical Trials 191
17.7.1 Jul 27, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 191
17.7.2 Jul 25, 2012: Bard Announces Enrollment Completion Of Lutonix Drug-Coated Balloon Clinical Trial And Initiation Of Large Continuation Registry Study 191
17.7.3 Jun 15, 2010: C.R. Bard Announces Publication Of RESILIENT Trial Results Of Bard LIFESTENT Vascular Stent 192
17.7.4 Feb 16, 2010: C.R. Bard To Complete Clinical Trial For Bard Ventrio Hernia Patch In First Half Of 2011 193
17.7.5 Sep 08, 2009: Bard To Complete Phase I Trial For RESTORe Suturing System In Second Half Of 2010 193
17.7.6 Sep 02, 2009: Bard To Complete The Phase III Trial For BARD HD MESH Ablation System In First Half Of 2011 194
17.7.7 Aug 20, 2008: C. R. Bard Inc. Published Clinical Study Results Of Agento I.C. Silver-Coated Endotracheal Tube 194
17.8 Other Significant Developments 195
17.8.1 Nov 28, 2012: Novation Awards Cardiovascular Agreements 195
17.8.2 Aug 15, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Wound Drainage Products 195
17.8.3 Mar 01, 2012: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Invasive Cardiology Equipment 195
17.8.4 Nov 14, 2011: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Electrophysiology Products 195
18 Appendix 196
18.1 Research Methodology 197
18.2 Secondary Research 197
18.3 Primary Research 197
18.4 Models 198
18.5 Forecasts 198
18.6 Expert Panels 198
18.7 GlobalData Consulting 198
18.8 Currency Conversion 199
18.9 Contact Us 200
18.10 Disclaimer 200
【レポート販売概要】
■ タイトル:C. R. Bard, Inc.:市場シェア分析■ 英文:C. R. Bard, Inc. Market Share Analysis
■ 発行日:2013年2月28日
■ 調査会社:GlobalData
■ 商品コード:GDATA403160482
■ 調査対象地域:グローバル
- 再発悪性神経膠腫:グローバル臨床試験レビュー(2014年上半期)Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the t …
- 2014 Leading Diagnostic Imaging Market Players : Analogic, Esaote, GE, Hitachi, Hologic, Philips, Shimadzu, Siemens, ToshibaThe companies analyzed in this report include Analogic, Esaote, GE, Hitachi, Hologic, Philips, Shimadzu, Siemens, and Toshiba. The report presents insightful strategic assessments, including:Business, new product development, and marketing strategies.Anticipated acquisitions, joint ventures, and divestitures.The U.S. and international sales force size in major geographic regions.Selling opti …
- 風力タービン用鋳造品の世界市場分析:タイプ別(水平軸、垂直軸)、用途別(オンショア、オフショア)、地域別(北アメリカ、ヨーロッパ、アジア太平洋、中南米、MEA)、セグメント予測、2014-2025The global wind turbine casting market is expected to reach USD 3.27 billion by 2025, according to a new report conducted by Grand View Research, Inc. The growing demand for electricity in developing countries including China, India, South Africa, and Brazil on account of increasing population and urbanization will drive the application of wind turbines. Furthermore, increasing government spending …
- M2Mサービスの世界市場2017-2021About Machine-to-Machine M2M ServicesA machine-to-machine (M2M) platform is a programmed unit in which M2M applications and services are built on. Owing to the growing adoption of the Internet of Things (IoT) and M2M services, the demand for innovative M2M platforms to enable new M2M services (such as connected cars and smart homes) is increasing. Also, many small players are entering the global M …
- 注入型薬物送達の世界市場:薬物送達デバイス、薬物送達製剤The injectable drug delivery market is expected to reach $547.8 billion by 2020 from $326.1 billion in 2015, growing at a CAGR of 12.0% from 2015 to 2020. The market is categorized on the basis of type, therapeutic application, usage pattern, mode of administration, end user, and region. The therapeutic application market is further segmented into autoimmune diseases, hormonal disorders, oncology, …
- セラミックフィルターの世界市場分析:製品別(水フィルター、エアーフィルター)、用途別(住宅、商業、工業、高温ガスろ過、油/水ろ過、バイオろ過)、セグメント予測 -2022GlobalCeramic Filters Market is expected to reach USD 2,139.4 million by 2022, according to a new study by Grand View Research, Inc. Favorable regulations for both water and air filtration across key regions is expected remain a key driving factor for global ceramic filters market. Superior quality and performance over its polymeric counterpart is also expected to have a positive influence on the …
- 手術ナビゲーションシステムの世界市場予測(~2021): 電磁的(EM)ナビゲーションシステム、ハイブリッドナビゲーションシステム、光学式ナビゲーションシステムThe global surgical navigation systems market is expected to reach USD 906.8 Million by 2021 from USD 662.5 Million in 2016, at a CAGR of 6.5% during the forecast period (2016–2021). The market is mainly driven by factors such as rising adoption of minimally invasive surgical procedures; growing number of partnerships, agreements, and collaborations among market players; increasing incidence of or …
- 自動車用スチールホイールの世界市場2018-2022About Automotive Steel Wheels Automotive steel wheels are circular shaped rims on which the tires are mounted. They are responsible for enabling mobility of an automobile and to carry the weight of the vehicle. From conventional cast-iron wheels to high-performance carbon fiber alloys, automotive wheels have evolved significantly in terms of the materials used to manufacture them. Technavio’s anal …
- IVF(体外受精)機器の世界市場2017-2021ABSTRACTAbout IVF Devices Infertility is a biological condition which refers to the inability of a person to reproduce. IVF is the most common and effective procedure helpful in assisting pregnancy. IVF is one of the most popular fertility techniques used to treat infertility and related problems in both genders. According to the Centers for Disease Control and Prevention (CDC), about 1.5-2.0 mill …
- データセンターアウトソーシングの世界市場2015-2019About Data Center Outsourcing Data centers are central repositories of servers, systems, storage devices, and networking equipment. Data center outsourcing is a process of outsourcing an enterprise's IT infrastructure and its management to third-party vendors that have expertise in deploying and maintaining data center facilities. These vendors provide end-to-end management of data center services …
- 浮遊式生産システム(FPS)の世界市場:FLNG、FPSO、半潜水型、SPAR、TLPVisiongain assesses that CAPEX on floating production systems will reach $16.91bn in 2015. This includes spending on floating liquefied natural gas (FLNG) vessels, floating production, storage and offloading (FPSO) vessels, semi-submersibles, single-point anchor reservoirs (SPARs) and tension-leg platforms (TLPs). Large vessels can take up to ten years from final investment decision to start-up da …
- 住宅用浄水器の世界市場2018-2022About Residential Water Purifier A residential water purifier is an appliance that eliminates undesirable chemicals, suspended solids, and biological contaminants from contaminated water. It aims to remove possible harmful impurities from untreated water and produce clean drinking water. Technavio’s analysts forecast the global residential water purifier market to grow at a CAGR of 16.83% during t …
- 自動車産業用ロボットの世界市場:マテリアルハンドリングロボット、組み立てロボット、溶接ロボット、塗装ロボットAbout Industrial Robotics Market in Automotive Industry Industrial robots were first adopted in the automotive industry in 1960 by GM and were called Unimate. These robots could weld and handle huge payloads. Wider adoption of robots started in 1980 in response to a need to automate applications such as welding, painting, and assembling in the automotive industry. Although robots were expensive, c …
- 半導体パッケージング材料の世界市場:有機基板、ボンディングワイヤー、リードフレーム、封止樹脂、セラミックパッケージ、ダイアタッチ材、半田ボールAbout Semiconductor Packaging Materials Semiconductor packages are metal, plastic, and ceramic components which not only protect the fabricated IC on the semiconductor die but also acts as an interconnect between the die and the PCB (printed circuit board). They protect the die from external mechanical impact and corrosion, and also act as electrically conductive interconnects with excellent signa …
- 環境制御システムの世界市場予測(~2022年)The environmental control systems market is estimated to grow from USD 3.27 Billion in 2016 to USD 4.22 Billion by 2022, at a CAGR of 4.34% from 2016 to 2022. Technological advancements in environmental control systems and growth in air traffic are the major factors driving the environmental control systems market and technological advancements. On the basis of system, the thermal management & con …